Antiarrhythmic drugs–clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)
Top Cited Papers
Open Access
- 9 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (5), 731-732an
- https://doi.org/10.1093/europace/eux373
Abstract
No abstract availableThis publication has 197 references indexed in Scilit:
- Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgeryEmergencias, 2013
- Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillationEP Europace, 2012
- Novel pharmacological targets for the rhythm control management of atrial fibrillationPharmacology & Therapeutics, 2011
- Cardiovascular PharmacogenomicsCirculation Research, 2011
- Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction*Critical Care Medicine, 2011
- Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillationEP Europace, 2010
- Drug-Induced Long QT SyndromePharmacological Reviews, 2010
- Prevention of Torsade de Pointes in Hospital SettingsCirculation, 2010
- Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trialsEuropean Heart Journal, 2009
- Effect of dronedarone on renal function in healthy subjectsBritish Journal of Clinical Pharmacology, 2007